SOC+ BSB-2002 Clinical Trials (2026): 1 Studies for AML - Acute Myeloid Leukemia & AML With Mutated NPM1
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 SOC+ BSB-2002 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including AML - Acute Myeloid Leukemia & AML With Mutated NPM1) and 19 total planned enrollment. 1 SOC+ BSB-2002 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07566585 (Sep 2027).
Where to Participate: All SOC+ BSB-2002 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting SOC+ BSB-2002trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MO | Washington University at St Louis | St Louis63110 | NCT07566585 | Map |
SOC+ BSB-2002 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting SOC+ BSB-2002 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07566585 | AMLDose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation | P1 | AML - Acute Myeloid Leukemia | 19 | Apr 2026 |
All SOC+ BSB-2002 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07566585 | AML | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation | P1 | recruiting | 19 | BlueSphere Bio, Inc | Apr 2026 |
SOC+ BSB-2002 clinical trials: frequently asked questions
- How many SOC+ BSB-2002 clinical trials are there?
- 1 SOC+ BSB-2002 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are SOC+ BSB-2002 clinical trials recruiting in 2026?
- Yes — 1 SOC+ BSB-2002 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is SOC+ BSB-2002 being studied for?
- SOC+ BSB-2002 is being studied for AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent. The trials are grouped by indication on this page.
- What phase is SOC+ BSB-2002 in?
- SOC+ BSB-2002 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors SOC+ BSB-2002 clinical trials?
- The lead sponsor across the most SOC+ BSB-2002 trials is BlueSphere Bio, Inc. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SOC+ BSB-2002as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: